

# Scapa Group PLC

## Result of AGM

RNS Number : 5459V  
Scapa Group PLC  
07 August 2020

7 August 2020

LEI No. 213800QIPVTK5ES5UU36

**Scapa Group plc**  
**('Scapa' or 'the Company')**  
**Result of AGM**

The Annual General Meeting for 2020 of Scapa Group plc (AIM: SCPA) was held on Friday, 7 August 2020 at the offices of Scapa Group plc, Manchester Road, Ashton-under-Lyne, Greater Manchester OL7 0ED.

A poll was held on each of the resolutions proposed and each resolution was passed. Resolutions 1 to 11 and 15 were passed as ordinary resolutions and resolutions 12 to 14 were passed as special resolutions.

| Resolution  | For                    | Against               | Withheld   |
|---|------------------------|-----------------------|------------|
| 1 To receive the Annual Report and Accounts of the Company for the financial year ended 31 March 2020 | 102,477,067<br>100%*   | 0<br>0.00%*           | 2,000      |
| 2 To approve the Directors' Remuneration Report for the financial year ended 31 March 2020.           | 65,258,508<br>76.14%*  | 20,453,019<br>23.86%* | 16,767,540 |
| 3 To elect Chris Brinsmead as a Director  | 102,467,565<br>100%*   | 0<br>0.00%*           | 11,502     |
| 4 To re-elect Heejae Chae as a Director   | 102,465,691<br>100%*   | 0<br>0.00%*           | 13,376     |
| 5 To re-elect Oskar Zahn as a Director  | 102,464,591<br>99.99%* | 1,100<br>0.01%*       | 13,376     |
| 6 To re-elect David Blackwood as a Director   | 89,234,202<br>87.09%*  | 13,231,489<br>12.91%* | 13,376     |
| 7 To re-elect Brendan McAtamney as a Director   | 90,195,650<br>88.03%*  | 12,270,041<br>11.97%* | 13,376     |
| 8 To elect Tim Miller as a Director   | 102,404,343<br>99.94%* | 62,862<br>0.06%*      | 11,862     |
| 9 To reappoint Deloitte LLP as auditor of the Company   | 102,048,641<br>99.99%* | 3,552<br>0.01%*       | 426,874    |
| 10 To authorise the Directors to fix the remuneration of the auditor                                  | 102,473,608<br>99.99%* | 485<br>0.01%*         | 4,974      |
|   |                        |                       |            |

|   |                        |                       |            |
|---|------------------------|-----------------------|------------|
| 11 To authorise the Directors to allot shares   | 84,028,325<br>82.0%*   | 18,441,382<br>18.0%*  | 9,360      |
| 12 To authorise the Directors to dis-apply pre-emption rights in relation to the customary 5% power pursuant to the statement of principles dis-applying pre-emption rights         | 82,996,946<br>81.0%*   | 19,472,761<br>19.0%*  | 9,360      |
| 13 To authorise the Directors to dis-apply pre-emption rights in relation to the additional 5% power to be used in connection with an acquisition or a specified capital investment | 80,543,615<br>78.61%*  | 21,915,490<br>21.39%* | 19,962     |
| 14 To authorise the Company to make market purchases of its own shares  | 85,021,904<br>99.03%*  | 831,398<br>0.97%*     | 16,625,765 |
| 15 To authorise the Company to make political donations   | 100,031,652<br>97.67%* | 2,383,541<br>2.33%*   | 63,874     |

\* as a percentage of votes cast

As announced on 23 June 2020, following this morning's AGM, Larry Pentz has now stepped down as Chairman and is succeeded by Chris Brinsmead who was appointed to the Board today. The Board would like to extend its thanks to Larry for his guidance and support and wish him well for the future.

The Board would like to thank its shareholders for their engagement and support ahead of the AGM and throughout the year. While all resolutions proposed at the AGM were passed with significant majorities, the Board notes that Resolutions 2 and 13 were passed with more than 20% of votes cast against them. In advance of the AGM, the Board developed a clear understanding of the concerns raised by shareholders on each of these resolutions.

In the period ahead, the Board, under the stewardship of its newly appointed Chair, will continue to consult and engage with shareholders in order to foster further understanding of their expectations and views. The outcome of these engagements will be detailed in next year's Annual Report and Accounts.

For further information:

Scapa Group plc: +44 (0) 161 301 7400  
Wendy Baker  
Company Secretary  
Numis Securities Limited: +44 (0) 20 7260 1000  
Mark Lander/Freddie Barnfield  
(Joint Broker/Nominated Adviser)

### **About Scapa Group plc**

Scapa Group plc is a diversified Healthcare and Industrial company focused on bringing best-in-class innovation, design and manufacturing solutions to its customers.

#### **Healthcare**

Scapa Healthcare is the trusted strategic partner of choice for the world's leading companies in Advanced Wound Care, Consumer Wellness and Medical Device Fixation. We partner with the top global MedTech companies to develop and manufacture innovative skin friendly medical device fixation and topical solutions, from inception through to market delivery, from our state-of-the-art facilities.

For further information, please visit [www.scapahealthcare.com](http://www.scapahealthcare.com)

#### **Industrial**

Scapa Industrial is a global supplier of bonding solutions and manufacturer of adhesive-based products which offer meaningful value in industrial applications due to their lightweight, easy-to-apply properties. We are recognised for our unparalleled range of products, including adhesive tapes, films and foams, and we can engineer custom designs for even the most unique applications.

For further information, please visit [www.scapaindustrial.com](http://www.scapaindustrial.com)

